CN108350025B - 用于蛋白质聚乙二醇化的添加剂体系 - Google Patents

用于蛋白质聚乙二醇化的添加剂体系 Download PDF

Info

Publication number
CN108350025B
CN108350025B CN201680067897.7A CN201680067897A CN108350025B CN 108350025 B CN108350025 B CN 108350025B CN 201680067897 A CN201680067897 A CN 201680067897A CN 108350025 B CN108350025 B CN 108350025B
Authority
CN
China
Prior art keywords
peg
protein
reaction
pegylation
additive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680067897.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN108350025A (zh
Inventor
M.R.希基
A.拉米雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to CN202211743414.4A priority Critical patent/CN115819494A/zh
Publication of CN108350025A publication Critical patent/CN108350025A/zh
Application granted granted Critical
Publication of CN108350025B publication Critical patent/CN108350025B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201680067897.7A 2015-11-23 2016-11-22 用于蛋白质聚乙二醇化的添加剂体系 Active CN108350025B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211743414.4A CN115819494A (zh) 2015-11-23 2016-11-22 用于蛋白质聚乙二醇化的添加剂体系

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258644P 2015-11-23 2015-11-23
US62/258644 2015-11-23
PCT/US2016/063313 WO2017091568A1 (en) 2015-11-23 2016-11-22 Additive systems for use in protein pegylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211743414.4A Division CN115819494A (zh) 2015-11-23 2016-11-22 用于蛋白质聚乙二醇化的添加剂体系

Publications (2)

Publication Number Publication Date
CN108350025A CN108350025A (zh) 2018-07-31
CN108350025B true CN108350025B (zh) 2023-02-21

Family

ID=57589163

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211743414.4A Pending CN115819494A (zh) 2015-11-23 2016-11-22 用于蛋白质聚乙二醇化的添加剂体系
CN201680067897.7A Active CN108350025B (zh) 2015-11-23 2016-11-22 用于蛋白质聚乙二醇化的添加剂体系

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211743414.4A Pending CN115819494A (zh) 2015-11-23 2016-11-22 用于蛋白质聚乙二醇化的添加剂体系

Country Status (17)

Country Link
US (3) US10617765B2 (enExample)
EP (2) EP3789395B1 (enExample)
JP (2) JP6921821B2 (enExample)
KR (1) KR102688003B1 (enExample)
CN (2) CN115819494A (enExample)
CY (1) CY1123699T1 (enExample)
DK (1) DK3380487T3 (enExample)
ES (1) ES2827776T3 (enExample)
HR (1) HRP20201832T1 (enExample)
HU (1) HUE052634T2 (enExample)
LT (1) LT3380487T (enExample)
PL (1) PL3380487T3 (enExample)
PT (1) PT3380487T (enExample)
RS (1) RS61072B1 (enExample)
SI (1) SI3380487T1 (enExample)
SM (1) SMT202000649T1 (enExample)
WO (1) WO2017091568A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3380487T1 (sl) * 2015-11-23 2020-11-30 Bristol-Myers Squibb Company Sistemi dodatkov za uporabo pri pegilaciji proteinov
JP7441826B2 (ja) * 2018-09-11 2024-03-01 アンブルックス，インコーポレイテッド インターロイキン－２ポリペプチド抱合物およびその使用
CN111484551B (zh) * 2020-03-19 2022-02-11 北京翼方生物科技有限责任公司 一种聚乙二醇修饰的重组人碱性成纤维细胞生长因子

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056448A2 (en) * 2005-11-08 2007-05-18 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
EP1885404A2 (en) * 2005-06-01 2008-02-13 Alza Corporation Bioconjugation reactions for acylating polyethlene glycol reagents
JP2012116840A (ja) * 2004-03-17 2012-06-21 Anticancer Inc タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE19734293A1 (de) 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
KR20140012199A (ko) * 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
JP6508781B2 (ja) 2013-01-30 2019-05-08 アベラス バイオサイエンシーズ，インク． 選択的な送達分子及びその使用方法
US20160082119A1 (en) 2013-04-22 2016-03-24 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
SI3380487T1 (sl) * 2015-11-23 2020-11-30 Bristol-Myers Squibb Company Sistemi dodatkov za uporabo pri pegilaciji proteinov

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012116840A (ja) * 2004-03-17 2012-06-21 Anticancer Inc タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法
EP1885404A2 (en) * 2005-06-01 2008-02-13 Alza Corporation Bioconjugation reactions for acylating polyethlene glycol reagents
WO2007056448A2 (en) * 2005-11-08 2007-05-18 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides;Liu C C 等;《Annu.Rev.Biochem.》;20101231;413 *

Also Published As

Publication number Publication date
JP6921821B2 (ja) 2021-08-18
US20200276319A1 (en) 2020-09-03
SI3380487T1 (sl) 2020-11-30
WO2017091568A8 (en) 2018-01-04
JP2021176890A (ja) 2021-11-11
CN115819494A (zh) 2023-03-21
CY1123699T1 (el) 2022-03-24
JP7257457B2 (ja) 2023-04-13
SMT202000649T1 (it) 2021-01-05
PL3380487T3 (pl) 2020-12-28
US10617765B2 (en) 2020-04-14
HRP20201832T1 (hr) 2021-01-08
LT3380487T (lt) 2020-12-28
PT3380487T (pt) 2020-10-29
HUE052634T2 (hu) 2021-05-28
KR20180081610A (ko) 2018-07-16
US11213589B2 (en) 2022-01-04
KR102688003B1 (ko) 2024-07-23
EP3789395B1 (en) 2025-08-27
RS61072B1 (sr) 2020-12-31
EP3380487B1 (en) 2020-09-02
EP3789395A1 (en) 2021-03-10
DK3380487T3 (da) 2020-12-07
CN108350025A (zh) 2018-07-31
JP2019503994A (ja) 2019-02-14
US20220160883A1 (en) 2022-05-26
ES2827776T3 (es) 2021-05-24
WO2017091568A1 (en) 2017-06-01
US20190351065A1 (en) 2019-11-21
EP3380487A1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
JP7257457B2 (ja) タンパク質のｐｅｇ化に用いるための添加物系
KR100445564B1 (ko) 기질결합된고리형유기화합물의조합라이브러리
CN110105434A (zh) 钉合且缝合的多肽及其用途
WO2001085733A1 (en) Interstrand crosslinking agents for dna and compounds therefor
Somehsaraie et al. Chemical wastes in the peptide synthesis process and ways to reduce them
Guthrie et al. Ketoxime peptide ligations: oxidative couplings of alkoxyamines to N-aryl peptides
Tsuji et al. Extent of helical induction caused by introducing α-aminoisobutyric acid into an oligovaline sequence
Byun et al. Preparation of polymer-bound pyrazolone active esters for combinatorial chemistry
US20180079715A1 (en) Method for producing alkylamine derivative and its production intermediate of alkylamine derivative
Misawa et al. Rational design and synthesis of post-functionalizable peptide foldamers as helical templates
Dou et al. Copper (II) Triflate‐Catalyzed Three‐Component Coupling of Aldehydes, Alkynes and Carbamates
Fu et al. Regioselective oxidative cleavage of conjugated dienes to access α, β-unsaturated nitriles
Shao et al. A new polymer-bound N-hydroxysuccinimidyl active ester linker
KR101692992B1 (ko) 고리형 펩타이드의 사전 활성화 합성방법 및 이에 따라 합성된 고리형 펩타이드
Neo et al. Allylic amination of Passerini adducts. Application to the selective synthesis of chromone-substituted α-and γ-amino acid peptidic and retropeptidic units
CN109485580B (zh) 一种艾曲波帕中间体的合成方法
CN1575272A (zh) 制备4－亚硝基取代的芳香胺的方法
US6198002B1 (en) Preparation of secondary and tertiary 2-methyl-1, 5-pentanediamines
Boer The Development of Potent, Broad Spectrum Norbornane-based Antibacterial Agents
Islam Cyclization-Based Site-Selective N-Terminal Cysteine Conjugation, Peptide Stapling and Histone Deacetylase (HDAC) Probing
Monty Development of a Synthetic Toolkit for the Exploration of All-Hydrocarbon α-Helical Stapled Peptide Chemical Space via DNA-Encoded Chemical Libraries
Zangana Synthesis of Amino Acids from Chiral NiII Schiff Base Complexes for Novel Stapled Peptides
CN104262167A (zh) 一种二芳胺衍生物的制备方法
Palla Development and Applications of N-terminal Protein Bioconjugation Reactions
Méret Development of an efficient and flexible method for the solid-phase synthesisof n-hydroxypolyamine derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant